Core Points - Sinovac Biotech Ltd. is facing significant compliance challenges that may lead to its delisting from NASDAQ [3] - The company received a delisting decision from NASDAQ on November 12, 2025, due to its failure to submit the 2024 annual 20-F report by the deadline of November 11, 2025 [3] - Sinovac has appointed UHY LLP as its new independent auditor and is working diligently to complete the annual report audit and submission [5][6] Compliance Issues - The delisting decision is based on the company's non-compliance with NASDAQ listing rule 5250(c)(1) [3] - Unless the company requests a hearing from the NASDAQ hearing panel in a timely manner, its securities will face suspension and delisting risk starting November 21, 2025 [3] Actions Taken - Sinovac is actively communicating with NASDAQ and plans to apply for an extension for the annual report submission deadline [6] - The company is preparing to argue its case regarding the delisting issue in a hearing [6]
科兴生物回应“纳斯达克退市”